Company Directory - Repare Therapeutics Inc.
Company Details - Repare Therapeutics Inc.
Repare Therapeutics Inc.
A biotechnology company focused on developing novel therapeutics for the treatment of cancer based on DNA repair pathways.
CCI Score
CCI Score: Repare Therapeutics Inc.
-54.90
0.03%
Latest Event
Repare Therapeutics Cuts 75% of Workforce in Major Restructuring
Repare Therapeutics announced a major restructuring plan involving a 75% reduction in its workforce to extend cash reserves, following a previous round of layoffs in August 2024 and the end of its collaboration with Roche earlier in 2024.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
QUISLING
Repare Therapeutics Inc. is currently rated as a Quisling.
Latest Events
- FEB262025
Repare Therapeutics announced a major restructuring plan involving a 75% reduction in its workforce to extend cash reserves, following a previous round of layoffs in August 2024 and the end of its collaboration with Roche earlier in 2024.
-80
Labor Relations and Human Rights Practices
March 29
The decision to cut 75% of the workforce represents a severe undermining of labor rights and worker stability. From an anti-fascist perspective, such drastic layoffs contribute to economic disenfranchisement of workers, prioritizing financial survival over employee welfare, and indicate a concerning disregard for fair labor practices.
Repare Therapeutics to cut 75% of workforce in major restructuring
- FEB252025
Repare Therapeutics announced drastic layoffs, cutting approximately 75% of its workforce—from 179 employees to fewer than 35—in a reorganization that also includes the departure of its chief medical officer. The move is part of a strategic shift to prioritize its clinical-stage oncology programs, with expected annual savings of about $21 million.
-80
Labor Relations and Human Rights Practices
March 29
The company's decision to slash its workforce by approximately 75% represents a severe undermining of worker rights and job security. This drastic action devalues the contributions and livelihoods of its employees, reflecting a broader pattern of corporate behavior that neglects the welfare of its workforce, an issue central to labor relations and human rights practices.
- JAN092025
Repare Therapeutics announced a strategic re-alignment of its clinical portfolio involving cost and headcount reductions aimed at extending its cash runway into mid-2027, while focusing on key Phase 1 clinical programs and seeking new partnering opportunities.
-30
Labor Relations and Human Rights Practices
March 29
The announcement of cost and headcount reductions raises concerns over labor rights and worker security. From an anti-fascist perspective that advocates for strong worker protections, such moves are viewed negatively as they potentially undermine fair labor practices.
- JAN092025
Repare Therapeutics announced a realignment of its resources including a re-prioritization of its clinical portfolio and planned cost and headcount reductions. The measures are intended to extend the company’s cash runway but may negatively impact employee welfare.
-50
Labor Relations and Human Rights Practices
March 29
The announcement of significant cost-cutting measures and planned headcount reductions signals a deprioritization of worker security and fair labor practices. From an anti-fascist, worker-rights perspective, such moves can contribute to economic disenfranchisement of employees, thereby reflecting negatively on the company’s ethical responsibility in labor relations.
- JAN092025
Repare Therapeutics Inc. announced a strategic re-prioritization of its clinical portfolio, emphasizing its Phase 1 clinical programs and plans for partnered development, alongside cost-saving initiatives that include headcount reductions.
-40
Labor Relations and Human Rights Practices
March 29
The announcement outlines planned cost and headcount reductions which may adversely affect worker rights and stability. Although intended to extend the company’s cash runway and secure future development, these measures risk undermining fair labor practices and employee welfare, a concern from an anti-fascist and pro-worker rights perspective.
Alternatives
Dallas, United States
44.45
Corporation
63.97
Corporation
11.46
Corporation
0.00
Corporation
0.00
Corporation
0.00
Corporation
0.00
Corporation
0.00
Corporation
0.00
Corporation
0.00
Industries
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 621510
- Medical Laboratories